Health

A new $3.2 billion program will support the development of antiviral pills, which could start arriving by the end of this year.

An analysis of health insurance records of almost two million coronavirus patients found new issues in nearly a quarter — including those whose Covid infection was mild or asymptomatic.

More than half of the cases were reported in people ages 12 to 24. Not all are likely to be verified or related to vaccines, and experts believe the benefits of immunization far outweigh the risk of these complications.

The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients.

Important immune cells survive in the bone marrow of people who were infected with the virus or were inoculated against it, new research suggests.

The agency is reviewing several dozen reports that teenagers and young adults may have developed myocarditis after vaccination, officials said. But the agency has not determined whether the vaccine caused the condition.